Device Trial Radar · NCT07626645
Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Feb 1, 2027
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Gazi UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Lower extremity lymphedema is a chronic and progressive condition associated with significant functional impairment and reduced quality of life. The current gold-standard treatment is Complex Decongestive Therapy (CDT); however, a substantial proportion of patients continue to experience persistent symptoms during the maintenance phase. This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of Extracorporeal Shock Wave Therapy (ESWT) as an adjunct to standard CDT maintenance therapy in patients with lower extremity lymphedema. Participants will be randomly allocated to either an active ESWT group or a sham ESWT group, with both groups continuing standard CDT maintenance throughout the study. ESWT will be administered twice weekly for five sessions. Changes in limb volume, skin thickness and subcutaneous tissue thickness assessed by ultrasonography, pain, functional status, and quality of life will be evaluated at baseline, after treatment, and at one-month follow-up.
Conditions
- Lymphedema, Lower Limb
- Extracorporeal Shock Wave Therapy
- Edema Leg
- Sham-controlled
- Placebo Control Design
Interventions
Extracorporeal Shock Wave Therapy (ESWT)Device
Radial shock wave therapy will be applied using the EMS Swiss DolorClast® device. Each session will consist of 3,000 impulses delivered at 20 Hz and 2 bar using a 40 mm applicator, targeting fibrotic tissue regions and periinguinal and peripopliteal lymph node areas. ESWT will be administered twice weekly for five sessions
Sham Extracorporeal Shock Wave Therapy (Sham ESWT)Device
Sham ESWT will be applied with identical positioning and session duration as the active ESWT group. Only non-energized impulses will be delivered, ensuring participant blinding. Sham ESWT will be administered twice weekly for five sessions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Lower Extremity Limb VolumeTime frame: Baseline, immediately after treatment (week 3), and 1-month follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gazi University Hospital, Department of Physical Medicine and Rehabilitation, Ankara, 06560
Ankara, Yenimahalle, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.